1. At a Glance – India’s Lab King or Just a Fancy Test Tube Seller?
If Indian science labs had a Tinder profile, their “long-term relationship” would be with Borosil. From school chemistry labs to hardcore pharma giants making life-saving injectables, this company is basically the silent partner behind half the experiments in India. And yet… the stock behaves like it just failed practical exams.
Here’s the drama:
Revenue is growing. Profit just jumped 132% YoY in Q3. Market share in lab glassware is allegedly above 50%. Brand recall? Legendary. Debt? Practically non-existent.
And still — the market is like: “Meh.”
Why?
Because beneath this shiny glassware empire lies a messy lab experiment:
- One segment is booming (scientific glassware)
- Two segments are struggling (pharma packaging + process equipment)
- Margins are doing yoga (stretching, shrinking, unpredictable)
It’s like having one topper child and two cousins who keep failing CA attempts.
So the real question is:
👉 Is Borosil Scientific building India’s scientific backbone… or just burning cash trying to diversify?
2. Introduction – The Great Borosil Family Drama
Let’s start with the family tree — because this is not a normal company, this is a full Bollywood joint family.
The Borosil group split itself like a property dispute:
- Borosil Ltd → consumer glassware
- Borosil Renewables → solar glass
- Borosil Scientific → lab and pharma stuff
And in June 2024, Borosil Scientific finally got listed. New kid on the stock market block.
Now here’s the thing:
This company has 60+ years legacy in lab glassware.
Translation:
When your school lab broke a beaker in 2008, chances are it was Borosil.
But instead of chilling with its dominant market share, management decided:
👉 “Let’s diversify!”
So now they do:
- Lab glassware (OG business)
- Lab equipment (LabQuest brand)
- Pharma packaging (ampoules & vials)
- Process systems (via Goel Scientific acquisition)
Basically, they went from “glass seller” to “full scientific ecosystem builder.”
Sounds ambitious, right?
Yes… but also risky.
Because every time an Indian company says “diversification,” an investor somewhere quietly whispers:
👉 “Margins ka kya hoga?”
3. Business Model – WTF Do They Even Do?
Let’s simplify this before your brain starts overheating.
Core Business (The Hero)
- Lab glassware (beakers, flasks, etc.)
- Used in pharma, biotech, research labs
- High brand loyalty
- Recurring demand
This segment is like Virat Kohli in a run chase — reliable, consistent, no drama.
New Businesses (The Risky Side Characters)
1. Lab Equipment (LabQuest)
- Instruments like mixers, analyzers, etc.
- Mostly imported market → opportunity to replace imports
Good idea… but execution still cooking.
2. Pharma Packaging
- Glass vials & ampoules for injectables
- Used in pharma companies
Sounds sexy… but currently struggling with demand + efficiency issues.
3. Process Systems (Goel Scientific)
- Chemical process reactors, industrial systems
- High margin potential… but currently weak order book
This segment literally had sales reversal in Q3.
Yes… negative growth in a “growth segment.”
Conclusion of Business Model
So what do they actually do?
👉 Sell glassware (cash cow)
👉 Experiment with new verticals (cash burn?)
Now
